Neonatal sepsis: an old problem with new insights

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Biomarker Discovery

Background:

• Neonatal sepsis is a major health concern, especially for very-low-birth-weight (VLBW) infants.
• While group B Streptococcus infections have decreased, sepsis from Escherichia coli is rising in VLBW preterm infants.
• Nonspecific symptoms of neonatal sepsis complicate early diagnosis and treatment.

Purpose of the Study:

• To review current diagnostic markers for neonatal sepsis.
• To highlight the need for more accurate and valid biomarkers.
• To explore promising novel markers for early sepsis detection.

Main Methods:

• Review of existing literature on neonatal sepsis diagnostic markers.
• Analysis of hematological indices, acute phase reactants, C-reactive protein, procalcitonin, cytokines, and cell surface markers.
• Evaluation of emerging biomarkers such as inter α inhibitor proteins.

Main Results:

• Numerous diagnostic markers have been studied, but none offer consistently high accuracy.
• Inter α inhibitor proteins demonstrate potential as a promising new biomarker for neonatal sepsis.
• Reliable early identification of sepsis is crucial to reduce unnecessary antibiotic use and improve infant outcomes.

Conclusions:

• Further research is essential to identify highly accurate biomarkers for neonatal sepsis.
• Novel markers like inter α inhibitor proteins may significantly improve early detection rates.
• Accurate early diagnosis is paramount for optimizing treatment and enhancing survival in VLBW infants with sepsis.